Idiopathic pulmonary fibrosis, also known as cryptogenic fibrosing alveolitis, is one of a family of idiopathic pneumonias sharing the clinical features of shortness of breath, radiographically ...

Panelists discuss how effective management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) relies on early, accurate diagnosis and multidisciplinary collaboration ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, which impairs oxygen exchange and leads to breathing difficulties.

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. May 1 2022;205(9):e18 ...

Idiopathic pulmonary fibrosis is a fatal disease without effective therapy or diagnostic test. To investigate a potential role for γ−herpesviruses in this disease, 21 paraffin-embedded lung ...

Idiopathic pulmonary fibrosis (IPF) (or cryptogenic fibrosing alveolitis (CFA) / or Idiopathic Fibrosing Interstitial Pneumonia) is a chronic, progressive form of lung disease characterized by ...

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease that causes scar tissue to grow inside your lungs. Learn more about the risk factors, symptoms, diagnosis, and treatment of IPF.

Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management. Download the Supplement.

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung condition. IPF causes scar tissue to build up in the lungs, leading to shortness of breath and a persistent cough. According ...

Find all the latest on idiopathic pulmonary fibrosis at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.

Idiopathic pulmonary fibrosis appears to be increasing in incidence. It requires early recognition and intervention with supportive care and pharmacologic agents to forestall its progression. Lung ...